BI 51013
Alternative Names: Anti-alpha-beta-TCR monoclonal antibody BMA-031; Anti-T cell receptor alphabeta monoclonal antibody BMA031; Anti-TCR-alphabeta monoclonal antibody BMA031;… See moreLatest Information Update: 26 Jan 2017
Price :
$50 *
At a glance
- Originator Aventis Behring LLC
- Developer Aventis Behring
- Class Monoclonal antibodies
- Mechanism of Action T-cell receptor antigen alpha-beta antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Graft-versus-host disease; Renal transplant rejection; Transplant rejection
Most Recent Events
- 25 Jan 2017 Discontinued - Phase-II for Graft-versus-host disease in Germany, USA (unspecified route)
- 25 Jan 2017 Discontinued - Phase-III for Renal transplant rejection in USA, Germany (IV)
- 25 Jan 2017 Discontinued - Preclinical for Transplant rejection in Japan (unspecified route)